

Orphan Drug Development Guidebook

Building Block I408

This document defines the content of the Building Block created for each identified tool, incentives, initiative or practice introduced by public bodies or used by developers to expedite drug development in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	BBMRI-ERIC - European research infrastructure for biobanking.
References	http://www.bbmri-eric.eu/
Description	<p>BBMRI-ERIC is a European research infrastructure for biobanking. We bring together all the main players from the biobanking field – researchers, biobankers, industry, and patients – to boost biomedical research. To that end, we offer quality management services, support with ethical, legal and societal issues, and a number of online tools and software solutions. Ultimately, our goal is to make new treatments possible. BBMRI-ERIC Expert Centres are non-profit organisations that represent a novel public-private partnership model. They are responsible for the analysis of samples in the country of origin under internationally standardised conditions and for the generation of primary data. BBMRI-ERIC Expert Centres integrate pre-competitive public and private research and development activities by providing access not only to biological samples and medical data but also to the broad spectrum of medical and scientific expertise related to the samples, data, and their analysis.</p> <p>The directory is the central listing of Biobanks and their collections in the BBMRI-ERIC member states. For researchers, the Directory offers a means of finding relevant samples and data for their research. Rare Disease Biobanks have a separate section in the directory.</p>
Category	Development Resources Building Block

Geographical scope	European Union
Availability	Applicants developing medicines for rare and non-rare diseases.
Scope of use	Test biomarkers analyze data. Pre-clinical development work. Biobanks provide biomaterials & data derived from those http://www.bbmri-eric.eu/fag/
Stakeholders	<ul style="list-style-type: none"> • Biobank holders • Academia • Industry • Civil society • Patient organisations
Enablers/ Requirements	It is not completely clear from the website who is entitled access.
Output	Biomaterials & Data thereof
Best time to apply and time window	The tool has its use during R&D phase.
Expert tips	Check early if information on your disease is included in this infrastructure.